



Faculty disclosures report

The 2025 COMy Congress seeks to balance the important benefits of physician-industry relationships with the potential risk that the financial goals of the industry may conflict with the professional goals of COMy participants. In doing so, the 2025 COMy Congress recognizes that it has a profound duty to its participants, the larger medical community and the public to ensure the integrity of all its scientific, educational, and advocacy activities and materials.

Educational Content Development

The 2025 COMy Congress requires all Program members and any others in a position to control the educational content to disclose any commercial financial interests prior to the development of the educational content. A process of resolution of conflict of interest is used for those members who do have financial interests related to the development of the content.

Presenters

The 2025 COMy Congress considers financial relationships to create actual conflicts of interest when presenters have both a financial relationship with a commercial interest and the opportunity to affect the policy of the 2025 COMy Congress of CME about the products or services of that commercial interest. The potential for Presenter to maintaining or increasing the value of the financial relationship with the commercial interest creates an incentive to influence the content of the CME – an incentive to insert commercial bias. All presenters of CME content should familiarize themselves with the policy of the 2025 COMy Congress of CME based on the CME providers of the Congress.

All 2025 COMy Faculty presenting CME are required to disclose the following prior to beginning their presentation:

- Any relevant financial relationships a CME presenter has had with manufacturers of commercial products or providers of commercial services within the past 12 months. The 2025 COMy Congress defines "relevant" financial relationships as those with a commercial interest and the opportunity to affect the content of CME about the products or services of that commercial interest
- CME presenters who report they have no known relevant financial relationships to disclose will declare "No Financial Relationships"

2025 COMy Financial Disclosure Codes

Type of affiliation / financial interest	Code
Honorarium	H
Consultant	C
Advisory Boards	A
Research Funding	R
Speakers' Bureau	S
Employee	E
Other	<i>Written as stated on submitted form</i>
Nothing to declare	<i>Written as said statement</i>



Disclosure Information

Financial interest disclosures from program members and others in a position for control content:

Kenneth Anderson, USA

C Astra Zeneca, Janssen, Pfizer
A Dynamic Cell Therapies, C4 Therapeutics, Next RNA, Oncopeptides, Starton Therapeutics, Window Therapeutics, Predicta

Hervé Avet-Loiseau, France

Nothing to declare

Nizar Bahlis, Canada

A AbbVie, Pfizer, Janssen, BMS, Sanofi

Meral Beksac, Turkey

A Amgen, BMS, Janssen, GSK, Takeda, Menarini Stemline
R Janssen
S Janssen, BMS, Takeda, GSK, Sanofi, Menarini Stemline

Claudio Cerchione, Italy

A,C,S AbbVie, Amgen, Astellas, Beigene, BMS, Curis, Glycomimetics, GSK, Immunogen, Janssen, Jazz, Karyopharm, Menarini Stemline, Oncopeptides, Pfizer, Sanofi, Servier, Skyline DX, Takeda

Jill Corre, France

H Janssen, Takeda, Amgen, Sanofi, BMS, Pfizer, Adaptive
R Sanofi, BMS

Binod Dhakal, USA

H BMS, Janssen, Karyopharm
C Genentech, Pfizer
A Pfizer, Arcellx, Kite, Janssen, Karyopharm, Genentech, Natera, Astra Zeneca, Caribou, Sanofi
R Caribou, Arcellx, Janssen, Pfizer, Sanofi, BMS, Carsgen, Ichnos, C4 Therapeutics
S BMS, Janssen, Karyopharm, Sanofi

Meletios Dimopoulos, Greece

H,C,A Amgen, Sanofi, Regeneron, Menarini, Takeda, GSK, BMS, Janssen, Beigene, Swixx, Astra Zeneca

Audelia Eshel-Fuhrer, Israel

Nothing to declare

Carlos Fernández de Larrea, Spain

H Amgen, J&J, BMS, GSK, Sanofi, Pfizer, BeiGene
A J&J, BMS, Amgen, Pfizer, Sanofi, BeiGene, GSK, Roche, Menarini
R BMS, J&J, Amgen, GSK

Irene Ghobrial, USA

H Vor Biopharma, Janssen, MJH Life Sciences, Novartis, Takeda, Amgen, Janssen, Regeneron, Curio Science, Standard Biotools
C BMS, Astra Zeneca, Amgen, Curio Science, Sanofi, Janssen, Pfizer, Menarini Silicon Biosystems, Aptitude Health, GSK, AbbVie, Adaptive, BMS, Window Therapeutics, Regeneron
A Predicta Biosciences

Hartmut Goldschmidt, Germany

Nothing to declare



The 11th World Congress on Controversies in Multiple Myeloma (COMy)
May 15-18, 2025 - Paris, France & Online
comy.cme-congresses.com

Sigurdur Kristinsson, Iceland

Nothing to declare

Shaji Kumar, USA

C AbbVie, Amgen, ArcellX, BeiGene, BMS, Carsgen, GSK, Janssen, K36, Moderna, Pfizer, Regeneron, Roche-Genentech, Sanoofi, Takeda, CVS Caremark, BD Biosciences

R AbbVie, Amgen, Astra Zeneca, BMS, Carsgen, GSK, Gracell Bio, Janssen, Oricell, Roche-Genentech, Sanofi, Takeda, Telogenomics

Xavier Leleu, France

H Kite/Gilead, Janssen, BMS, GSK, Roche, Novartis, Sanofi, Roche, Pfizer

Suzanne Lentzsch, USA

A Pfizer, Janssen, GSK, Sanofi, BMS, Karyopharm, Angitia, Alexion

R Sanofi, Zentails

S Regeneron, PeerView, Clinical Care Options, RedMed, Aptitude, Medscape, Springer Healthcare

Other: DSMB-Regeneron, Janssen, BMS; Royalties, Patents: Caelum Bioscience

Sagar Lonial, USA

A Takeda, Amgen, Novartis, BMS, GSK, AbbVie, Genentech, Pfizer, Regeneron, Janssen

R Novartis, BMS, Janssen, Takeda

Other: Board of Directors with stock: TG Therapeutics

Florent Malard, France

H BMS, Astra Zeneca, Therakos/Mallinckrodt, Sanofi, Jazz Pharma, Gilead, Novartis, Priothera, Astellas

Salomon Manier, France

C,A AbbVie, Adaptive, Amgen, Celgene/BMS, GSK, Janssen, Novartis, Regeneron, Roche, Sanofi, Takeda

R BMS, Janssen

S Janssen, BMS, Amgen

Joaquín Martínez López, Spain

Nothing to declare

María-Victoria Mateos, Spain

Nothing to declare

Francesco Maura, USA

C Medidata

Philippe Moreau, France

H, A Janssen, Celgene/BMS, Amgen, Takeda, AbbVie, Pfizer, Sanofi

Nikhil Munshi, USA

C AbbVie, Adaptive Bio, Amgen, BMS, Celgene, GSK, Janssen, Karyopharm, Legend, Novartis, Oncopeptides, Pfizer, Recordati, Sebia, Takeda

Robert Orlowski, USA

A AbbVie, Adaptive, Asyilia Therapeutics, BioTheryX, BMS, DEM BioPharma, Karyopharm, Lytixa Therapeutics, Meridian Therapeutics, Monte Rosa Therapeutics, Myeloma 360, Nanjing IASO Biotherapeutics, Neoleukin Corporation, Oncopeptides, Pfizer, Regeneron, Sanofi, Sporos Bioventures, Takeda

R BMS, Carsgen, Exelixis, Heidelberg Pharma, Janssen, Sanofi, Takeda, Asyilia Therapeutics, BioTheryX



The 11th World Congress on Controversies in Multiple Myeloma (COMy)
May 15-18, 2025 - Paris, France & Online
comy.cme-congresses.com

Aurore Perrot, France

H AbbVie, Adaptive, Amgen, BMS, GSK, Janssen, Menarini, Pfizer, Sanofi, Takeda

Noemi Puig, Spain

H The Binding Site *part of Thermofisher*

Marc Raab, Germany

H BMS, Janssen, Amgen, Sanofi, Oncopeptides

C BMS, Janssen, Amgen, Sanofi, GSK, Pfizer, Takeda, AbbVie

A BMS, Janssen, Sanofi, Pfizer

R BMS, Janssen, Heidelberg Pharma

Noopur Raje, USA

C BMS, Janssen, Pfizer, Amgen, Takeda, AbbVie, Sanofi

A Caribou Bio

R bluebird bio

Vincent Rajkumar, USA

Nothing to declare

Paul Richardson, USA

C Celgene/BMS, GSK, Karyopharm, Oncopeptides, Regeneron, Sanofi

R Oncopeptides

Joshua Richter, USA

C BMS, Pfizer, Karyopharm, Sanofi, Takeda, Genentech, AbbVie, Regeneron, Forus, Menarini

S Janssen, BMS, Sanofi, Adaptive

Paula Rodríguez-Otero, Spain

H,C Roche, J&J, BMS, Pfizer, GSK, AbbVie

A Roche, J&J, BMS, Pfizer, GSK, AbbVie, Regeneron

R Pfizer

S J&J, Pfizer

Mehmet Samur, USA

Nothing to declare

Pieter Sonneveld, Netherlands

A Janssen, Pfizer, Oncopeptides, Karyopharm

R Janssen, Amgen, Sanofi, Karyopharm, Pfizer

Andrew Spencer, Australia

Nothing to declare

Keith Stewart, Canada

A Pfizer, J&J, BMS, Sanofi

Evangelos Terpos, Greece

H,A Amgen, Astra Zeneca, EUSA Pharma, BMS, GSK, J&J, Menarini Stemline, Pfizer, Sanofi, Takeda

R Amgen, GSK, J&J, Sanofi, Takeda

Other: Takeda, *travel grant*

Cyrille Touzeau, France

H,C,A J&J, Pfizer, Amgen, AbbVie, Takeda, BMS, Sanofi



The 11th World Congress on Controversies in Multiple Myeloma (COMy)
May 15-18, 2025 - Paris, France & Online
comy.cme-congresses.com

Steven Treon, USA

A Janssen, BeiGene, ONO Pharmaceuticals

Saad Usmani, USA

C AbbVie, Amgen, BMS, Celgene, EdoPharma, Genentech, Gilead, GSK, Janssen, Oncopeptides, Sanofi, Seattle Genetics

R AbbVie, Amgen, Array Biopharma, BMS, Celgene, GSK, Gilead, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics

Kwee Yong, UK

Nothing to declare

Elena Zamagni, Italy

H,A BMS, Sanofi, Pfizer, Janssen, GSK, Oncopeptides

Sonja Zweegman, Netherlands

R Takeda, Janssen

C Takeda, Janssen, BMS/Celgene, Sanofi, Oncopeptides, Amgen